Trastuzumab-DM1 (T-DM1; biosimilar of Kadcyla®) was synthesized and was tested in an in vitro efficacy assay employing an in vivo xenograft model.
The following results demonstrate the in-house T-DM1 has comparable tumor inhibition activity and in vivo PK profiles comparing to reported data of Kadcyla.
Acute toxicity of T-DM1 was assessed. Results showed tested ADC products are well tolerated at the tested dosages
In vivo efficacy results from T-DM1 case study using NCl-N87 gastric cancer xenograft model. Data showed full regression of tumor after treatment with 15mg/kg of ADC.
